Continuing patients were randomized ( @:@:@ ratio ) to alirocumab @ mg self-administered via single @ mL prefilled pen every @ weeks or ezetimibe @ mg/day or atorvastatin @ mg/day ( statin rechallenge ) , for @ weeks .